Co-Authors
This is a "connection" page, showing publications co-authored by Ming-Hua Zheng and Giovanni Targher.
Connection Strength
4.437
-
Detrimental effects of metabolic dysfunction-associated fatty liver disease and increased neutrophil-to-lymphocyte ratio on severity of COVID-19. Diabetes Metab. 2020 11; 46(6):505-507.
Score: 0.885
-
Risk of severe illness from COVID-19 in patients with metabolic dysfunction-associated fatty liver disease and increased fibrosis scores. Gut. 2020 08; 69(8):1545-1547.
Score: 0.882
-
Patients with diabetes are at higher risk for severe illness from COVID-19. Diabetes Metab. 2020 09; 46(4):335-337.
Score: 0.882
-
Association and Interaction Between Serum Interleukin-6 Levels and Metabolic Dysfunction-Associated Fatty Liver Disease in Patients With Severe Coronavirus Disease 2019. Front Endocrinol (Lausanne). 2021; 12:604100.
Score: 0.233
-
ACE2: A Linkage for the Interplay Between COVID-19 and Decompensated Cirrhosis. Am J Gastroenterol. 2020 09; 115(9):1544.
Score: 0.225
-
Abnormal liver enzymes in children and infants with COVID-19: A narrative review of case-series studies. Pediatr Obes. 2020 12; 15(12):e12723.
Score: 0.225
-
Extrapulmonary complications of COVID-19: A multisystem disease? J Med Virol. 2021 01; 93(1):323-335.
Score: 0.223
-
Diabetes as a risk factor for greater COVID-19 severity and in-hospital death: A meta-analysis of observational studies. Nutr Metab Cardiovasc Dis. 2020 07 24; 30(8):1236-1248.
Score: 0.221
-
Subclinical Acute Kidney Injury in COVID-19 Patients: A Retrospective Cohort Study. Nephron. 2020; 144(7):347-350.
Score: 0.221
-
Obesity Is a Risk Factor for Greater COVID-19 Severity. Diabetes Care. 2020 Jul; 43(7):e72-e74.
Score: 0.220
-
COVID-19 and Liver Dysfunction: Current Insights and Emergent Therapeutic Strategies. J Clin Transl Hepatol. 2020 Mar 28; 8(1):18-24.
Score: 0.219